| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SRDX | Common Stock | Options Exercise | $88,106 | +4,366 | +13% | $20.18 | 36,951 | 14 Nov 2022 | Direct | |
| transaction | SRDX | Common Stock | Sale | $91,507 | -2,773 | -7.5% | $33.00 | 34,178 | 14 Nov 2022 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SRDX | Stock Option (right to buy) | Options Exercise | $0 | -4,366 | -100% | $0.000000* | 0 | 14 Nov 2022 | Common Stock | 4,366 | $20.18 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Reflects the weighted average price of 2,773 shares of common stock of Surmodics, Inc. sold by the reporting person in multiple transactions on November 14, 2022 with sale prices ranging from $32.9021 to $33.18 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F2 | The amount beneficially owned includes 11,985 restricted stock units (RSUs) that vest on service-based vesting dates and 15,415 DSUs that are vested upon issuance, each of which will be settled in shares of the issuer's common stock on a 1 for 1 basis when the reporting person's service as a director ends. |
| F3 | Fully vested. |